Treatment, Medication & Supplement Directory
A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.
Named profile Palladia (Toceranib): Approved Canine Mast Cell Tumor Targeted TherapyRepresentative category illustration – no product packaging is shown.Palladia (Toceranib): Approved Canine Mast Cell Tumor Targeted Therapy
Palladia is an FDA-approved prescription veterinary tyrosine kinase inhibitor for treatment of Patnaik grade II or III recurrent canine cutaneous mast cell tumors, with or without regional lymph-node…
Read more
Named profile Laverdia (Verdinexor): FDA-Approved Oral Therapy for Canine LymphomaRepresentative category illustration – no product packaging is shown.Laverdia (Verdinexor): FDA-Approved Oral Therapy for Canine Lymphoma
Verdinexor is an oral prescription antineoplastic for certain dogs with lymphoma. FDA announced full approval in January 2026 after the product's earlier conditional-approval pathway; publication should use the…
Read more
Omega-3 Fatty Acid Support: Product, Dose, and Evidence Questions
Omega-3 products are nutritional supplements, not cancer treatments. EPA and DHA content, total calories, oxidation control, formulation, and quality vary widely, and evidence from one condition or diet…
Read more
Tyrosine Kinase Inhibitors: A Class-Level Monitoring Framework
Tyrosine kinase inhibitors are not one interchangeable drug class; target profile, label, evidence, dosing, monitoring, and adverse effects differ by product and patient.
Read more
Imatinib in Canine Mast Cell Tumor Care: Extra-Label Evidence Review
Imatinib has published canine mast cell tumor experience but is not interchangeable with veterinary-labeled TKIs and requires specialist, legal, formulation, and evidence review.
Read more
Named profile Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell TumorsRepresentative category illustration – no product packaging is shown.Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell Tumors
Masitinib is an oral canine TKI with an EMA veterinary authorization for a defined mast cell tumor setting; the current regional label governs eligibility and monitoring.
Read more
Medicinal Mushroom Extracts: Product-Specific Oncology Evidence
Mushroom products differ by species, extracted fraction, standardization, contaminants, and evidence; the word mushroom does not identify a tested intervention.
Read more
Turmeric and Curcumin: Bioavailability, Interaction, and Evidence Limits
Turmeric and curcumin products vary in extract, concentration, absorption enhancers, and purity, while robust canine cancer outcome evidence is lacking.
Read more
CBD and Cannabis Products in Pets With Cancer: Regulatory and Safety Boundary
FDA has not approved CBD for animal use, and product quality, THC contamination, interactions, liver effects, sedation, legal status, and cancer claims require caution.
Read more
Chinese Herbal Formulas: Identification, Quality, and Evidence Review
A named traditional formula can vary by translation, ingredient, species, processing, manufacturer, and practitioner modification, so exact identification comes before benefit or safety claims.
Read more
Yunnan Baiyao-Type Hemostasis Discussion: Preclinical Evidence Is Not Bleeding Control
Yunnan Baiyao is used anecdotally in veterinary bleeding plans, but formulation opacity and limited clinical evidence do not support relying on it to prevent or stop tumor hemorrhage.
Read more
Probiotics and Synbiotics During Cancer Treatment: Strain-Specific Evidence
Probiotic effects are strain-, combination-, product-, storage-, and condition-specific, and immune compromise changes the safety conversation.
Read more